<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">microcirculation</journal-id><journal-title-group><journal-title xml:lang="ru">Регионарное кровообращение и микроциркуляция</journal-title><trans-title-group xml:lang="en"><trans-title>Regional blood circulation and microcirculation</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1682-6655</issn><issn pub-type="epub">2712-9756</issn><publisher><publisher-name>Academician I.P. Pavlov First St. Petersburg State Medical University</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.24884/1682-6655-2023-22-3-34-40</article-id><article-id custom-type="elpub" pub-id-type="custom">microcirculation-1213</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ (КЛИНИЧЕСКИЕ ИССЛЕДОВАНИЯ)</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES (CLINICAL INVESTIGATIONS)</subject></subj-group></article-categories><title-group><article-title>Свободные легкие цепи иммуноглобулинов и ремоделирование миокарда у пациентов с гломерулопатиями</article-title><trans-title-group xml:lang="en"><trans-title>Immunoglobulin free light chains and cardiac remodeling in glomerulopathies</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0917-0375</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Чурко</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Churkо</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Чурко Анна Аркадьевна – ассистент кафедры пропедевтики внутренних болезней</p><p>197022, Санкт-Петербург, ул. Льва Толстого, д. 6-8</p></bio><bio xml:lang="en"><p>Churko Anna A. – Assistant Professor, Department of Propaedeutics of Internal Diseases</p><p>6-8, L’va Tolstogo str., Saint Petersburg, 197022</p></bio><email xlink:type="simple">churko.anna@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9455-1043</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Румянцев</surname><given-names>А. Ш.</given-names></name><name name-style="western" xml:lang="en"><surname>Rumyantsev</surname><given-names>A. Sh.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Румянцев Александр Шаликович – д-р мед. наук, профессор кафедры факультетской терапии</p><p>197022, Санкт-Петербург, ул. Льва Толстого, д. 6-8;</p><p>199034 Санкт-Петербург, Университетская набережная, д. 7/9</p></bio><bio xml:lang="en"><p>Rumyantsev Alexandr Sh. – MD, Professor, Department of Faculty Therapy</p><p>6-8, L’va Tolstogo str., Saint Petersburg,197022;</p><p>7/9, Universitetskaya embankment, Saint Petersburg, 199034  </p></bio><email xlink:type="simple">rash.56@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0586-468X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Панина</surname><given-names>И. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Panina</surname><given-names>I. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Панина Ирина Юрьевна – д-р мед. наук, профессор кафедры пропедевтики внутренних болезней</p><p>197022, Санкт-Петербург, ул. Льва Толстого, д. 6-8</p></bio><bio xml:lang="en"><p>Panina Irina Yu. – Professor, Department of Propaedeutics of Internal Medicine</p><p>6-8, L’va Tolstogo str., Saint Petersburg, 197022 </p><p> </p></bio><email xlink:type="simple">i.u.panina@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Федеральное государственное бюджетное образовательное учреждение высшего образования «Первый Санкт-Петербургский государственный медицинский университет имени академика И. П. Павлова» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Pavlov University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Федеральное государственное бюджетное образовательное учреждение высшего образования «Первый Санкт-Петербургский государственный медицинский университет имени академика И. П. Павлова» Министерства здравоохранения Российской Федерации;  Федеральное государственное бюджетное образовательное учреждение высшего образования &#13;
«Санкт-Петербургский государственный университет»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Pavlov University;  Saint-Petersburg University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>16</day><month>10</month><year>2023</year></pub-date><volume>22</volume><issue>3</issue><fpage>34</fpage><lpage>40</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Чурко А.А., Румянцев А.Ш., Панина И.Ю., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Чурко А.А., Румянцев А.Ш., Панина И.Ю.</copyright-holder><copyright-holder xml:lang="en">Churkо A.A., Rumyantsev A.S., Panina I.Y.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.microcirc.ru/jour/article/view/1213">https://www.microcirc.ru/jour/article/view/1213</self-uri><abstract><p>Введение. Cвободные легкие цепи (СЛЦ) иммуноглобулинов в настоящее время рассматриваются как полноценные участники воспалительного процесса и эндотелиальной дисфункции не только при плазмаклеточных дискразиях, но и при ряде аутоиммунных заболеваний. Было показано, что повышение их уровня в сыворотке крови может являться неблагоприятным фактором снижения выживаемости как в общей популяции, так и у пациентов с хронической болезнью почек (ХБП). Широкого изучения роли пСЛЦ в патогенезе гломерулярных заболеваний как причины развития почечной дисфункции не проводилось. Целью нашего исследования была оценка взаимосвязи между СЛЦ и показателями ремоделирования миокарда в когорте пациентов с гломерулопатиями. Материалы и методы. Обследованы 97 пациентов с хронической болезнью почек, средний возраст 47,5±14,6 лет, среди них 51 мужчина и 46 женщин. У всех обследуемых диагноз различных гломерулопатий был подтвержден морфологически. Уровень пСЛЦ сыворотки крови был определен нефелометрическим методом «Freelite» («Binding Site Ltd», Великобритания). Скорость клубочковой фильтрации (рСКФ) рассчитывали по формуле «2021 CKD-EPI Creatinine». Также проводили эхокардиографию с оценкой параметров ремоделирования камер сердца. Результаты. Медиана рСКФ составила 46,8 мл/мин/1,73 м2 (28,7–80,0), уровень СЛЦ-каппа в группе составил 27,4 мг/л (16,8– 48,4), СЛЦ-лямбда – 28,2 мг/л (20,8–43,3). В целом уровень референсные значения для СЛЦ-каппа ((19,4 мг/л) и СЛЦ-лямбда (26,3 мг/л соответственно) были превышены соответственно у 65 % (n=63) и 54 % (n=52) пациентов. С помощью дU-критерия Манна–Уитни удалось выявить достоверные различия средних при нормальном и повышенном уровне пСЛЦ и индексом массы миокарда левого желудочка (ИММЛЖ) для СЛЦ-каппа 99,9±31,2 г/м2  против 138,3±30,2 г/м2 , р=0,022, для СЛЦ-лямбда 104,0±36,6 г/м2  против 136,2±64,8 г/м2, p=0,023. Индекс объема левого предсердия (ЛП) также достоверно был выше при более высоких значениях СЛЦ-лямбда (33,8±8,0 мл/м2  против 40,3±11,6 мл/м2 , р=0,031). Корреляционный анализ также продемонстрировал убедительные взаимосвязи показателей ремоделирования сердца и уровня пСЛЦ. Заключение. Уровень пСЛЦ в сыворотке крови отражает активность локального тканевого иммунного воспаления и эндотелиальной дисфункции. Полученные данные свидетельствуют об участии пСЛЦ в механизмах ремоделирования миокарда как одного из этапов кардиоренального континуума при гломерулопатиях различного генеза.</p></abstract><trans-abstract xml:lang="en"><p>Introduction. The role of polyclonal free light chains (pFLC) of immunoglobulins in glomerular diseases is still unknown despite the fact that their elevation predicts a poor prognosis in patients with chronic kidney disease (CKD). One of the possible persuasive mechanisms is the formation of low-grade inflammation which could be the reason for endothelial dysfunction and progression of a cardio-renal continuum. The aim was to estimate the possible association between serum FLC and several parameters of cardiac remodeling in the glomerulopathic patients’ cohort. Materials and methods. We examined 97 patients (51 men and 46 women, average age 48±14,6 years) with biopsy-proven glomerulopathies. We used Freelite (Binding Site Ltd, UK) to measure serum pFLC and other clinical and echocardiographic parameters. We calculated the glomerular filtration rate (eGFR) using the 2021 CKD-EPI Creatinine equation. We also performed echocardiography to measure some parameters of cardiac chamber remodeling. Results. Mean eGFR was 46.8 ml/min/1.73 m2 (28.7–80.0), the FLC-kappa level was 27.4 mg/l (16.8–48.4), the FLC-lambda level was 28.2 mg/l (20.8–43.3). The reference levels of FLC in the group were exceeded in 65 % for FLC-kappa and in 54% for FLC-lambda patients. A nonparametric Mann–Whitney U-test was performed to compare the effect of pFLC levels on the parameters of LV and LA geometry. If levels of FLC-kappa were higher than 19,4 mg/l, the left ventricular myocardium mass index (LVMMI) was statistically significantly bigger (99,9±31,2 g/m2  versus 138,3±30,2 g/m2 , р=0,022). If levels of FLC-lambda were higher than 26,3 mg/l, LVMMI was also bigger (104,0±36,6 g/m2  versus 136,2±64,8 g/m2, р=0,023). The left atrium (LA) volume index was also statistically significantly bigger at higher levels of FLC-lambda (33,8±8,0 ml/m2 versus 40,3±11,6 ml/m2, р=0,031). The Spearman analysis has shown statistically significant correlations between FLC levels, LVMMI and LA volume index. Conclusion. The serum pFLC level reflects the grade of local tissue immune inflammation and endothelial dysfunction. The obtained data indicate the involvement of pFLC in cardiac remodeling mechanisms as one of the important stages in the cardiorenal continuum in all types of glomerulopathies. </p></trans-abstract><kwd-group xml:lang="ru"><kwd>свободные легкие цепи</kwd><kwd>гломерулопатии</kwd><kwd>гипертрофия левого желудочка</kwd><kwd>ремоделирование миокарда</kwd><kwd>кардиоренальный континуум</kwd></kwd-group><kwd-group xml:lang="en"><kwd>free light chains</kwd><kwd>glomerulopathies</kwd><kwd>left ventricular hypertrophy</kwd><kwd>cardiac remodeling</kwd><kwd>cardiorenal continuum</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Jokiranta TS, Solomon A, Pangburn MK et al. Nephritogenic lambda light chain dimer: a unique human miniautoantibody against complement factor H // J Immunol. 1999; 163(8):4590–4596.</mixed-citation><mixed-citation xml:lang="en">Jokiranta TS, Solomon A, Pangburn MK et al. Nephritogenic lambda light chain dimer: a unique human miniautoantibody against complement factor H // J Immunol. 1999; 163(8):4590–4596.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Redegeld, FA, Nijkamp, FP. Immunoglobulin free light chains and mast cells: pivotal role in T-cell-mediated immune reactions? // Trends Immunol. 2003;24(4):181–185. Doi: 10. 1016/s1471-4906(03)00059-0.</mixed-citation><mixed-citation xml:lang="en">Redegeld, FA, Nijkamp, FP. Immunoglobulin free light chains and mast cells: pivotal role in T-cell-mediated immune reactions? // Trends Immunol. 2003;24(4):181–185. Doi: 10. 1016/s1471-4906(03)00059-0.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Особенности кардиоренального континуума у пациентов с метаболическим синдромом / Румянцев А.Ш., Шишкин А.Н., Минкин С.Р., Шевелева М.А. // Нефрология. – 2016. – Т. 20, № 5. – С. 75–83.</mixed-citation><mixed-citation xml:lang="en">Rumyantsev AS, Shishkin AN, Minkin SR, Sheveleva MA. Features of cardiorenal relationships in patients with metabolic syndrome // Nephrology. 2016;20(5):75–83. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Palladini G, Milani P, Merlini G. Management of AL amyloidosis in 2020 // Blood. 2020;136(23):2620–2627. Doi: 10.1182/blood.2020006913.</mixed-citation><mixed-citation xml:lang="en">Palladini G, Milani P, Merlini G. Management of AL amyloidosis in 2020 // Blood. 2020;136(23):2620–2627. Doi: 10.1182/blood.2020006913.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Смирнов А.В., Афанасьев Б.В., Поддубная И.В. и др. Моноклональная гаммапатия ренального значения: консенсус гематологов и нефрологов России по введению нозологии, диагностике и обоснованности клон-ориентированной терапии // Нефрология. – 2019. – Т. 23, № 6. – С. 9–28. Doi: 10.36485/1561-6274-2019-236-9-28.</mixed-citation><mixed-citation xml:lang="en">Smirnov AV, Afanasyev BV, Poddubnaya IV, Dobronravov VA, Khrabrova MS, Zakharova EV, Nikitin EA, Kozlovskaya LV, Bobkova IN, Rameev VV, Batyushin MM, Moiseev IS, Darskaya EI, Pirogova OV, Mendeleeva LP, Biryukova LS. Monoclonal gammopathy of renal signifi cance: Consensus of hematologists and nephrologists of Russia on the establishment of nosology, diagnostic approach and rationale for clone specific treatment // Nephrology. 2019;23(6):9–28. (In Russ.). Doi: 10.36485/1561-6274-2019-236-9-28.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Ying W, Wang P. Immunoglobulin light chains activate nuclear factor-κB in renal epithelial cells through a Src-dependent mechanism // Blood. 2011;117(4):1301–1307. Doi: 10.1182/blood-2010-08-302505.</mixed-citation><mixed-citation xml:lang="en">Ying W, Wang P. Immunoglobulin light chains activate nuclear factor-κB in renal epithelial cells through a Src-dependent mechanism // Blood. 2011;117(4):1301–1307. Doi: 10.1182/blood-2010-08-302505.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Taylor EB, Ryan MJ. Freedom isn’t always free: immunoglobulin free light chains promote renal fibrosis // J Clin Invest. 2019;129(7):2660–2662. Doi: 10.1172/JCI129704.</mixed-citation><mixed-citation xml:lang="en">Taylor EB, Ryan MJ. Freedom isn’t always free: immunoglobulin free light chains promote renal fibrosis // J Clin Invest. 2019;129(7):2660–2662. Doi: 10.1172/JCI129704.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Upadhyay R. Free light chains injure proximal tubule cells through the STAT1/HMGB1/TLR axis // JCI Insight. 2020; 5(14):e137191. Doi: 10.1172/jci.insight.137191.</mixed-citation><mixed-citation xml:lang="en">Upadhyay R. Free light chains injure proximal tubule cells through the STAT1/HMGB1/TLR axis // JCI Insight. 2020; 5(14):e137191. Doi: 10.1172/jci.insight.137191.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Wang Q, Jiang F, Xu G. The pathogenesis of renal injury and treatment in light chain deposition disease // J Transl Med. 2019;17(1):387. Doi: 10.1186/s12967-019-02147-4.</mixed-citation><mixed-citation xml:lang="en">Wang Q, Jiang F, Xu G. The pathogenesis of renal injury and treatment in light chain deposition disease // J Transl Med. 2019;17(1):387. Doi: 10.1186/s12967-019-02147-4.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Eymieux S, Miquelestorena-Standley E, Rabot N, Maisons V, Touchard G, Blanchard E. Crystalline podocytopathy and tubulopathy linked to kappa light chain deposits in a context of smoldering multiple myeloma // Clin Kidney J. 2021; 15(2):351–353. Doi: 10.1093/ckj/sfab197.</mixed-citation><mixed-citation xml:lang="en">Eymieux S, Miquelestorena-Standley E, Rabot N, Maisons V, Touchard G, Blanchard E. Crystalline podocytopathy and tubulopathy linked to kappa light chain deposits in a context of smoldering multiple myeloma // Clin Kidney J. 2021; 15(2):351–353. Doi: 10.1093/ckj/sfab197.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Jiang J, Zhao J, Liu D, Zhang M. Different roles of urinary light chains and serum light chains as potential biomarkers for monitoring disease activity in systemic lupus erythematosus // PeerJ. 2022;10:e13385. Doi: 10.7717/ peerj.13385.</mixed-citation><mixed-citation xml:lang="en">Jiang J, Zhao J, Liu D, Zhang M. Different roles of urinary light chains and serum light chains as potential biomarkers for monitoring disease activity in systemic lupus erythematosus // PeerJ. 2022;10:e13385. Doi: 10.7717/ peerj.13385.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Deng X, Crowson CS, Rajkumar SV, Dispenzieri A, Larson DR, Therneau TM, Matteson EL, Kyle RA, Katzmann JA, Gabriel SE, Davis JM 3rd. Elevation of serum immunoglobulin free light chains during the preclinical period of rheumatoid arthritis // J Rheumatol. 2015;42(2):181–187. Doi: 10.3899/ jrheum.140543.</mixed-citation><mixed-citation xml:lang="en">Deng X, Crowson CS, Rajkumar SV, Dispenzieri A, Larson DR, Therneau TM, Matteson EL, Kyle RA, Katzmann JA, Gabriel SE, Davis JM 3rd. Elevation of serum immunoglobulin free light chains during the preclinical period of rheumatoid arthritis // J Rheumatol. 2015;42(2):181–187. Doi: 10.3899/ jrheum.140543.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Gulli F, Napodano C, Marino M et al. Serum immunoglobulin free light chain levels in systemic autoimmune rheumatic diseases // Clin Exp Immunol. 2020;199(2):163–171. Doi:10.1111/cei.13385.</mixed-citation><mixed-citation xml:lang="en">Gulli F, Napodano C, Marino M et al. Serum immunoglobulin free light chain levels in systemic autoimmune rheumatic diseases // Clin Exp Immunol. 2020;199(2):163–171. Doi:10.1111/cei.13385.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Hutchison CA, Burmeister A, Harding SJ et al. Serum polyclonal immunoglobulin free light chain levels predict mortality in people with chronic kidney disease // Mayo Clin Proc. 2014;89(5):615–622. Doi:10.1016/j.mayocp.2014.01.028.</mixed-citation><mixed-citation xml:lang="en">Hutchison CA, Burmeister A, Harding SJ et al. Serum polyclonal immunoglobulin free light chain levels predict mortality in people with chronic kidney disease // Mayo Clin Proc. 2014;89(5):615–622. Doi:10.1016/j.mayocp.2014.01.028.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Rocchetti MT, Papale M, d’Apollo AM et al. Association of urinary laminin G-like 3 and free K light chains with disease activity and histological injury in IgA nephropathy // Clin J Am Soc Nephrol. 2013;8(7):1115–1125. Doi: 10.2215/ CJN.05950612.</mixed-citation><mixed-citation xml:lang="en">Rocchetti MT, Papale M, d’Apollo AM et al. Association of urinary laminin G-like 3 and free K light chains with disease activity and histological injury in IgA nephropathy // Clin J Am Soc Nephrol. 2013;8(7):1115–1125. Doi: 10.2215/ CJN.05950612.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Чурко А.А., Храброва М.С., Смирнов А.В. Поликлональные свободные легкие цепи при иммуноглобулин А-нефропатии: связь с клиническими и морфологическими параметрами и прогнозом // Нефрология. – 2021. – Т. 25, № 2. – С. 52–59. Doi: 10.36485/1561-6274-2021-25-2-52-59.</mixed-citation><mixed-citation xml:lang="en">Churko AA, Khrabrova MS, Smirnov AV. Polyclonal free light chains in IgA-nephropathy: correlation with clinical and morphological parameters and prognostic significance // Nephrology. 2021;25(2):52–59. (In Russ.). Doi: 10.36485/1561-6274-2021-25-2-52-59.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Панина И.Ю. Вазомоторная форма эндотелиальной дисфункции при хронической болезни почек // Нефрология. – 2006. – Т. 10, № 2. – С. 33–37. Doi: 10.24884/1561-6274- 2006-10-2-33-37.</mixed-citation><mixed-citation xml:lang="en">Panina IYu. Vasomotor form of endothelial dysfunction in chronic kidney disease // Nephrology. 2006;10(2):33–37. (In Russ.). Doi: 10.24884/1561-6274- 2006-10-2-33-37.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Matsumori A. Management of Atrial Fibrillation Using Immunoglobulin Free Light Chains, Novel Biomarkers of Inflammation // Eur Cardiol. 2022;17:e22. Doi: 10.15420/ ecr.2022.30.</mixed-citation><mixed-citation xml:lang="en">Matsumori A. Management of Atrial Fibrillation Using Immunoglobulin Free Light Chains, Novel Biomarkers of Inflammation // Eur Cardiol. 2022;17:e22. Doi: 10.15420/ ecr.2022.30.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Matsumori A. Targeting Inflammation in the Diagnosis, Management, and Prevention of Cardiovascular Diseases // Global Heart. 2022;17(1):80. Doi: 10.5334/gh.1156.</mixed-citation><mixed-citation xml:lang="en">Matsumori A. Targeting Inflammation in the Diagnosis, Management, and Prevention of Cardiovascular Diseases // Global Heart. 2022;17(1):80. Doi: 10.5334/gh.1156.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Inker LA, Eneanya ND, Coresh J et al. New Creatinineand Cystatin C-Based Equations to Estimate GFR without Race // N Engl J Med. 2021;385(19):1737–1749. Doi: 10. 1056/NEJMoa2102953.</mixed-citation><mixed-citation xml:lang="en">Inker LA, Eneanya ND, Coresh J et al. New Creatinineand Cystatin C-Based Equations to Estimate GFR without Race // N Engl J Med. 2021;385(19):1737–1749. Doi: 10. 1056/NEJMoa2102953.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Katzmann JA, Clark RJ, Abraham RS et al. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains // Clin Chem. 2002; 48(9):1437–1444.</mixed-citation><mixed-citation xml:lang="en">Katzmann JA, Clark RJ, Abraham RS et al. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains // Clin Chem. 2002; 48(9):1437–1444.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Long TE, Indridason OS, Palsson R et al. Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: Results of the iStopMM study // Blood Cancer J. 2022;12(9):133. Doi: 10.1038/s41408-022- 00732-3.</mixed-citation><mixed-citation xml:lang="en">Long TE, Indridason OS, Palsson R et al. Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: Results of the iStopMM study // Blood Cancer J. 2022;12(9):133. Doi: 10.1038/s41408-022- 00732-3.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Grunnet M, Bentzen BH, Sørensen US, Diness JG. Cardiac ion channels and mechanisms for protection against atrial fibrillation // Rev Physiol Biochem Pharmacol. 2012;162:1– 58. Doi: 10.1007/112_2011_3.</mixed-citation><mixed-citation xml:lang="en">Grunnet M, Bentzen BH, Sørensen US, Diness JG. Cardiac ion channels and mechanisms for protection against atrial fibrillation // Rev Physiol Biochem Pharmacol. 2012;162:1– 58. Doi: 10.1007/112_2011_3.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Yao Y, Yang M, Liu D, Zhao Q. Immune remodeling and atrial fibrillation // Front Physiol. 2022;13:927221. Doi: 10.3389/fphys.2022.927221.</mixed-citation><mixed-citation xml:lang="en">Yao Y, Yang M, Liu D, Zhao Q. Immune remodeling and atrial fibrillation // Front Physiol. 2022;13:927221. Doi: 10.3389/fphys.2022.927221.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Li S, Jiang Z, Chao X et al. Identification of key immune-related genes and immune infiltration in atrial fibrilla tion with valvular heart disease based on bioinformatics analysis // J Thorac Dis. 2021;13(3):1785–1798. Doi: 10.21037/ jtd-21-168.</mixed-citation><mixed-citation xml:lang="en">Li S, Jiang Z, Chao X et al. Identification of key immune-related genes and immune infiltration in atrial fibrilla tion with valvular heart disease based on bioinformatics analysis // J Thorac Dis. 2021;13(3):1785–1798. Doi: 10.21037/ jtd-21-168.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Xiao S, Zhou Y, Liu A et al. Uncovering potential novel biomarkers and immune infiltration characteristics in persistent atrial fibrillation using integrated bioinformatics analysis // Math Biosci Eng. 2021;18(4):4696–4712. Doi: 10.3934/ mbe.2021238.</mixed-citation><mixed-citation xml:lang="en">Xiao S, Zhou Y, Liu A et al. Uncovering potential novel biomarkers and immune infiltration characteristics in persistent atrial fibrillation using integrated bioinformatics analysis // Math Biosci Eng. 2021;18(4):4696–4712. Doi: 10.3934/ mbe.2021238.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Migrino RQ, Truran S, Gutterman DD, Franco DA, Bright M, Schlundt B, Timmons M, Motta A, Phillips SA, Hari P. Human microvascular dysfunction and apoptotic injury induced by AL amyloidosis light chain proteins // Am J Physiol Circ Physiol. 2011;301(6):H2305–H2312. Doi: 10.1152/ajpheart.00503.2011.</mixed-citation><mixed-citation xml:lang="en">Migrino RQ, Truran S, Gutterman DD, Franco DA, Bright M, Schlundt B, Timmons M, Motta A, Phillips SA, Hari P. Human microvascular dysfunction and apoptotic injury induced by AL amyloidosis light chain proteins // Am J Physiol Circ Physiol. 2011;301(6):H2305–H2312. Doi: 10.1152/ajpheart.00503.2011.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Migrino RQ, Hari P, Gutterman DD, Bright M, Truran S, Schlundt B, Phillips SA. Systemic and microvascular oxidative stress induced by light chain amyloidosis // Int J Cardiol. 2010;145(1):67–68. Doi: 10.1016/j.ijcard.2009.04.044.</mixed-citation><mixed-citation xml:lang="en">Migrino RQ, Hari P, Gutterman DD, Bright M, Truran S, Schlundt B, Phillips SA. Systemic and microvascular oxidative stress induced by light chain amyloidosis // Int J Cardiol. 2010;145(1):67–68. Doi: 10.1016/j.ijcard.2009.04.044.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Lavatelli F. Mechanisms of Organ Damage and Novel Treatment Targets in AL Amyloidosis // Hemato. 2022;3(1):47– 62. Doi: 10.3390/hemato3010005.</mixed-citation><mixed-citation xml:lang="en">Lavatelli F. Mechanisms of Organ Damage and Novel Treatment Targets in AL Amyloidosis // Hemato. 2022;3(1):47– 62. Doi: 10.3390/hemato3010005.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Townsend CL, Laffy JMJ, Wu Y-CB, Silva O’Hare J, Martin V, Kipling D, Fraternali F, Dunn-Walters DK. Significant Differences in Physicochemical Properties of Human Immunoglobulin Kappa and Lambda CDR3 Regions // Front. Immunol. 2016;7:388. Doi: 10.3389/fimmu. 2016.00388.</mixed-citation><mixed-citation xml:lang="en">Townsend CL, Laffy JMJ, Wu Y-CB, Silva O’Hare J, Martin V, Kipling D, Fraternali F, Dunn-Walters DK. Significant Differences in Physicochemical Properties of Human Immunoglobulin Kappa and Lambda CDR3 Regions // Front. Immunol. 2016;7:388. Doi: 10.3389/fimmu. 2016.00388.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
